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Steroid resistance is a major clinical challenge for both physicians and patients with a wide array of diseases, including NS, asthma, rheumatoid arthritis, and other inflammatory conditions primarily treated with steroids. NS is one of the most common forms of glomerular disease and one of the leading causes of end-stage kidney disease in both children and adults. Although GCs have been the primary therapy for NS for \>60 years, they unfortunately induce remission of NS in only approximately 50% of adults and approximately 80% of children,[@bib1]^,^[@bib2] with unresponsive patients being labeled as having SRNS. Unfortunately, no validated biomarkers have yet been identified that are able to predict steroid resistance, leaving patients at high risk for both toxic side effects of GC treatment, as well as disease progression. Thus, the identification and validation of biomarkers able to predict the clinical response to GC before the initiation of treatment could enable avoidance of GC-induced drug toxicity, and rapid initiation of alternative treatments more likely to induce remission and delay or prevent disease progression. In addition, the identification of candidate biomarkers able to determine specific molecular pathways and targets associated with clinical steroid resistance could enable the development of more effective and less toxic targeted future therapies for NS.

Mass spectrometric-based discovery proteomic methods have contributed significantly to our understanding of idiopathic renal disease by identification of proteins integral to disease processes.[@bib3]^,^[@bib4] State-of-the-art methods have the ability to characterize both high- and low-abundant proteins and develop both qualitative data to identify proteins and to suggest relative abundance or absolute concentration differences.[@bib5], [@bib6], [@bib7], [@bib8] These studies and other "omics" studies are providing valuable pilot and confirmatory information for the identification of disease biomarkers.[@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15] Recently, a few studies have approached urinary biomarker identification using proteomics in patients with NS either classified by histology or by clinical response.[@bib16]^,^[@bib17]

The present studies were designed to test the primary hypothesis that proteomic analyses with subsequent validation of paired plasma samples from children with SSNS and SRNS can be used to identify biomarkers predictive of steroid resistance at the time of disease presentation before therapy ([Figure 1](#fig1){ref-type="fig"}a). The secondary aim of the present study was to identify mechanistic molecular pathways or targets associated with clinical steroid resistance in NS ([Figure 1](#fig1){ref-type="fig"}b). To test this hypothesis, we analyzed paired plasma biosamples collected from 2008 to 2014 through the Midwest Pediatric Nephrology Consortium from children with NS that were obtained both at the time of disease presentation (before initiation of steroid therapy) and an average of approximately 7 weeks post-GC treatment, when the clinical determination of SRNS versus SSNS was made by the treating nephrologist.Figure 1Study hypothesis and design. The present studies were designed to test the hypothesis that proteomic analyses with subsequent validation in paired plasma samples from children with steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) can be used to identify biomarkers able to (a) predict clinical steroid resistance, and (b) mechanistically define specific molecular pathways or targets associated with clinical steroid resistance.

Methods {#sec1}
=======

Study Approval, Ethics Statement, Patients, and Plasma Collections {#sec1.1}
------------------------------------------------------------------

All research protocols and consent documents were approved by the institutional review board of Nationwide Children\'s Hospital as the coordinating center (approval numbers IRB07--00400, IRB12--00039, and IRB05--00544), as well as by each of the other participating centers of the Midwest Pediatric Nephrology Consortium. Paired plasma samples were collected for each patient, with the first sample "pretreatment" at the time of disease presentation before even a single dose of GC, and the second sample "post-treatment" after 6 to 10 weeks of GC therapy when the clinical determination of SSNS versus SRNS had been determined by the treating nephrologist. See [Table 1](#tbl1){ref-type="table"} for patient demographics and [Supplementary Methods](#appsec1) for clinical data and sample collection details.Table 1Patient demographics for proteomic discovery and Western blotting validation study cohorts*n*Discovery (proteomics)Validation (immunoblotting)TotalSSNSSRNS*P* valueTotalSSNSSRNS*P* value1578372413Weeks between pre- and post-treatment samples6.0 ± 0.5, *n* = 155.8 ± 0.7, *n* = 76.3 ± 0.7, *n* = 8ns6.9 ± 0.4, *n* = 376.9 ± 0.6, *n* = 246.7 ± 0.5, *n* = 13nsDisease onset samples verified to be pretreatment15 (100%)7 (100%)8 (100%)37 (100%)24 (100%)13 (100%)Age8.7 ± 1.0, *n* = 156.5 ± 1.7, *n* = 710.6 ± 0.9, *n* = 80.04[a](#tbl1fna){ref-type="table-fn"}7.0 ± 0.7, *n* = 355.6 ± 0.8, *n* = 229.5 ± 1.1, *n* = 130.006[b](#tbl1fnb){ref-type="table-fn"}Sex, *n* (%) Male0 (0)0 (0)0 (0)15 (42)11 (48)4 (31)[c](#tbl1fnc){ref-type="table-fn"}0.026[c](#tbl1fnc){ref-type="table-fn"} (2-tailed) Female15 (100)7 (100)8 (100)21 (58)12 (52)9 (69)[c](#tbl1fnc){ref-type="table-fn"}Not reported11 Height135.1 ± 6.4, *n* = 15118.8 ± 9.2, *n* = 7149.3 ± 5.2, *n* = 80.01[a](#tbl1fna){ref-type="table-fn"}124.5 ± 4.4, *n* = 36114 ± 4.5, *n* = 23143.1 ± 6.8, *n* = 130.0008[d](#tbl1fnd){ref-type="table-fn"} Weight43.9 ± 6.0, *n* = 1528.1 ± 5.0, *n* = 757.6 ± 7.5, *n* = 80.007[b](#tbl1fnb){ref-type="table-fn"}35.9 ± 3.9, *n* = 3625.9 ± 2.6, *n* = 2353.5 ± 7.6, *n* = 130.0002[d](#tbl1fnd){ref-type="table-fn"}Race, *n* (%) White9 (60)4 (57)5 (62.5)17 (46)11 (45.8)6 (46) Asian1 (7)1 (14.3)0 (0)4 (10.8)4 (16.7)0 (0) African American4 (27)1 (14.3)3 (37.5)10 (27)4 (16.7)6 (46)[e](#tbl1fne){ref-type="table-fn"}\<0.0001[e](#tbl1fne){ref-type="table-fn"} Biracial1 (7)1 (14.3)0 (0)2 (5.4)1 (4.2)1 (7.7) Native American0 (0)0 (0)0 (0)1 (2.7)1 (4.2)0 (0) Not reported0 (0)0 (0)0 (0)3 (8.1)3 (12.5)0 (0)[^4][^5][^6][^7][^8][^9][^10]

Proteomics Discovery Workflow {#sec1.2}
-----------------------------

The proteomics workflow ([Supplementary Figure S1](#appsec1)) addressed the label-free comparison of high mass accuracy data sets developed from 15 paired patient plasma samples (*n* = 30) using a fast protein liquid chromatography antibody-based method to immune-deplete the 20 most common plasma proteins before trypsinization. To address the limitation of small sample numbers and potential gender variability, the discovery proteomics dataset was developed with only female patient plasma samples, whereas the confirmation cohort was expanded to include both male and female patients. These data were then filtered to identify predictive and mechanistic biomarkers ([Figure 1](#fig1){ref-type="fig"}) and used for various other analyses described in [Supplementary Table S1](#appsec1). The data filtering approaches were directed by absolute or relative differences in the protein abundance, unbiased statistical or pathways approaches, and, last, expert review of the proteomic data. These procedures of "*Immuno-Depletion of Highly Abundant Proteins from Plasma, Sample Proteolysis and Liquid Chromatography--Mass Spectrometry (LCMS) Data Acquisition"* are detailed in the [Supplementary Material](#appsec1).

Informatics Analysis of LCMS Datasets {#sec1.3}
-------------------------------------

Proteome Discoverer (Thermo Fisher Scientific, Waltham, MA) v2.0.0.802 was used to analyze the data collected by the mass spectrometer with SequestHT searches performed using the July 7, 2015 version of the UniprotKB. See [Supplementary Methods](#appsec1) for details.

Immunoblot Analyses for Differential Protein Abundance {#sec1.4}
------------------------------------------------------

Plasma proteins were resolved on 6% to 20% gradient gels by sodium dodecyl sulfate--polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and immunoblotted as described in detail in the [Supplementary Material](#appsec1). X-ray films were scanned using a calibrated ArtixScan M1 transillumination scanner (Microtek Lab, Cerritos, CA) controlled by the ScanWizard Pro program (version 7.042, Microtek International Inc., Hsinchu, Taiwan; Microtek Lab Inc., Carson, CA) using standard settings. Densitometry analyses of the integrated band densities were performed using ImageJ (version 1.39, National Institutes of Health, Bethesda, MD, standard settings; <http://rsb.info.nih.gov/ij/>) and values plotted using GraphPad (LaJolla, CA) Prism software version 6.00 for Windows.

Statistical Evaluation of Trends in Protein Abundance {#sec1.5}
-----------------------------------------------------

### Discovery Proteomic Studies {#sec1.5.1}

To determine trends in protein abundance, all censored or missing values were replaced by a minimal global protein abundance value divided by the square root of 2 (minimal observed label-free signal ÷ √2) or 2280.3.[@bib18] The estimations for significance of the between-group protein abundance differences were calculated using medians of protein abundance and the Mann-Whitney 1-way analysis of variance. Protein name, gene name, accession numbers, and associated protein abundance values estimated as intensity-based absolute quantification values were exported into an Excel file from Scaffold.[@bib19] See [Supplementary Methods](#appsec1) for details.

### Targeted Validation Studies {#sec1.5.2}

Statistical significance was determined by unpaired or paired *t* tests using the GraphPad Prism software version 6.00 for Windows. *P* values were considered significant at *P* \< 0.05. Data shown include representative blots as well as quantitation of all the samples tested, and are displayed as means ± SEM. The ability of the quantified immunoblot data and patient sex to classify patient samples as SSNS and SRNS was determined using backward stepwise logistic regression analysis with −2log likelihood, Cox & Snell *R*^2^, and Nagelkerke *R*^2^ to assess goodness of fit for the reduced terms. The sensitivity and specificity for the reduced terms to classify patient samples was determined by the area under the curve from a receiver operator characteristic. Multivariate statistical tests were performed using SAS version 9.4 (SAS Inc., Cary, NC) and SPSS version 24 (IBM Corp., Armonk, NY).

Cluster Analysis With Heatmaps {#sec1.6}
------------------------------

To evaluate and illustrate group trends in protein relative abundance, the intensity-based absolute quantification data were analyzed by cluster analysis with heatmap illustration. To address the dynamic range differences across the proteomic data set, the protein intensity-based absolute quantification scores were normalized on a per protein level by conversion to a mean abundance fractional value across patient samples and rescaled to absolute values of 0 to 1 per row. These normalized, fractional abundance values were used for hierarchical clustering and heatmap generation using MatLab (2016b) (MathWorks, Natick, MA) and the function "clustergram."

Pathways Analyses {#sec1.7}
-----------------

The proteomic data (differentially regulated gene products with the Log2 fold change of SRNS to SSNS for both the pretreatment sample set and the post-treatment sample sets) were qualitatively assessed to provide approaches to functional annotation of data by submitting lists of identified proteins and expression patterns for pathways analysis using Ingenuity Pathways Analysis software (<http://ingenuity.com>). See [Supplementary Methods](#appsec1).

Results {#sec2}
=======

Patients and Demographics {#sec2.1}
-------------------------

Eighty-eight pediatric patients were enrolled over a 10-year period, although only approximately 50% of these patients (*n* = 45) were able to be enrolled before they received even a single dose of steroids. Of these, 37 patients with paired samples verified to include pretreatment samples and detailed clinical data were included in this study ([Table 1](#tbl1){ref-type="table"}). Twenty-four of these were clinically phenotyped as SSNS, because they achieved complete remission of proteinuria within an average of approximately 7 weeks of steroid therapy, whereas 13 patients did not achieve remission and were thus phenotyped as SRNS. Approximately equal numbers of children with SSNS (*n* = 7) and SRNS (*n* = 8) were used for the proteomics discovery studies, and only female patients were analyzed to compensate for potential gender variability. The validation cohort was expanded to include all available male and female patients. Children with SSNS were found to be different from those with SRNS in age, height, and weight, with SRNS patients presenting at a later age than those with SSNS (9.5 vs. 5.6 years; *P* = 0.006), consistent with known mean ages of presentation for these different forms of NS. To account for differences in pharmacodynamics of steroids in children with SSNS versus SRNS due to differences in weight, height, and body mass index, we calculated the average prescribed steroid dosage in the discovery cohort of these 2 groups. The differences in steroid dosage (SSNS, 1.81 ± 0.23 mg/kg per day vs. SRNS, 1.24 ± 0.14 mg/kg per day) were found to be not significantly different (nonparametric Mann-Whitney test; *P* \> 0.05). Moreover, African American patients comprised a greater percentage of SRNS patients than SSNS patients (46% vs. 17%; *P* \< 0.05).

Proteomic Profiling {#sec2.2}
-------------------

Paired pre- and post-treatment plasma samples (*n* = 30 samples; SSNS, *n* = 7 pairs; SRNS *n* = 8 pairs) were depleted of high abundant proteins, achieving a 95% high and moderate abundance protein depletion. A total of 226 proteins were identified by high-resolution 1D-liquid chromatography--mass spectrometry in both pre- and post-treatment SSNS and SRNS samples. Of the 20 immunodepletion targets, 9 (IgG, Transferrin, IgA, IgM, α1-acid glycoprotein, IgD, ceruloplasmin, plasminogen, and prealbumin) were sufficiently depleted so as to not be observed within the LCMS results. Three (haptoglobin, complement C1q, and α1-antitrypsin) were observed at low intensity-based absolute quantification scores across less than 30% of samples. Eight (alpha-2 macroglobulin; albumin; apolipoproteins-A1, -AII, and -B/; complement 3; complement C4; and fibrinogen) were observed in a large fraction (≥75%) of samples, although none achieved statistical difference between sample groups.

Identification of Candidate Biomarkers Able to Predict and Mechanistically Define Steroid Resistance {#sec2.3}
----------------------------------------------------------------------------------------------------

Protein lists were curated by requiring observation in at least 6 of 7 SSNS or 6 of 8 SRNS samples. This requirement resulted in 119 and 122 proteins, respectively, considered for subsequent statistical analysis. Following Wilcoxon and Mann-Whitney testing, 13 predictive ([Table 2](#tbl2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}b) and 66 mechanistic ([Table 3](#tbl3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}b) candidate biomarkers were retained for pathways analysis. The effects of steroid response on the relative abundance of the 13 predictive proteins is also illustrated in [Figure 2](#fig2){ref-type="fig"}a.[@bib20]Table 2Candidate biomarkers with potential to predict steroid resistance before therapyNameProteinDetection rate (SSNS)Detection rate (SRNS)*P* value (rank sum)Area ratio (SSNS:SRNS)Log2 (SSNS:SRNS)Protein functionCollagen alpha-3(VI) chainCOL6A386500.029.13.2Alpha chain of type VI Collagen that acts as a cell-binding protein and is implicated in muscle and connective tissue related diseasesInsulin-like growth factor-binding protein 2IGFBP2100630.0493.2Inhibits IGF-mediated growth and developmental rates. IGF-binding proteins prolong the half-life of the IGFs and either inhibit or stimulate the growth promoting effects of the IGFs by altering the interaction of IGFs with their cell surface receptors72 kDa type IV collagenaseMMP286630.032.31.2Ubiquitous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, atherosclerotic plaque rupture, and degradation of extracellular matrix proteinsApolipoprotein E[a](#tbl2fna){ref-type="table-fn"}APOE1001000.041.90.9Mediates the binding, internalization, and catabolism of lipoprotein particlesAdiponectinADIPOQ1001000.011.80.8Important adipokine involved in the control of fat metabolism and insulin sensitivity, with direct antidiabetic, anti-atherogenic and anti-inflammatory activitiesSex hormone--binding globulinSHBG1001000.031.80.8Functions as an androgen transport protein and regulates the plasma metabolic clearance rate of steroid hormonesEGF-containing fibulin-like extracellular matrix protein 1EFEMP11001000.011.60.7Binds EGFR, induces EGFR autophosphorylation and activation of downstream signaling pathwaysInter-alpha-trypsin inhibitor heavy chain H4ITIH41001000.011.40.5Also known as type II APP; it is involved in inflammatory response to traumaHemopexinHPX10010000.7−0.5Plasma protein with high affinity for heme and associates with HDL and influences its inflammatory propertiesVitamin D binding proteinVDB1001000.030.7−0.5Belongs to albumin gene family and major role is transport of various forms of Vitamin D metabolites; enhancement of the chemotactic activity of C5 alpha for neutrophils in inflammation and macrophage activationAntithrombin-IIISERPINC11001000.010.7−0.5Serine protease inhibitor in plasmaZinc-alpha-2-glycoproteinAZGP11001000.030.6−0.7Stimulates lipid degradation in adipocytesFetuin-BFETUB1001000.020.5−1Protease inhibitor[^11][^12]Table 3Candidate biomarkers with potential to identify mechanistic molecular pathways/targets of steroid resistanceNo.NameGene nameDifference pretreatmentSSNS post − pre[a](#tbl3fna){ref-type="table-fn"}SRNS post − pre[a](#tbl3fna){ref-type="table-fn"}Change with GC therapyGroup trend\[SSNS/SRNS\]Median proteomic (iBAQ) signal area*P* value signrankMedian proteomic (iBAQ) signal area*P* value signrankSSNSSRNS1Afamin (vitamin E binding protein)AFM1.21E+080.0161.80E+070.547↑[b](#tbl3fnb){ref-type="table-fn"}ns**Increase in both**2AngiotensinogenAGT2.62E+080.0311.45E+080.203↑[b](#tbl3fnb){ref-type="table-fn"}ns3Apolipoprotein DAPOD1.35E+070.8131.07E+080.016ns↑[b](#tbl3fnb){ref-type="table-fn"}4Apolipoprotein L1APOL17.98E+060.0164.26E+060.055↑[b](#tbl3fnb){ref-type="table-fn"}ns**5Alpha-2-glycoprotein 1, zinc-bindingAZGP10.65.02E+080.0313.63E+080.039↑**[b](#tbl3fnb){ref-type="table-fn"}**↑**[b](#tbl3fnb){ref-type="table-fn"}6Carboxypeptidase B2CPB21.09E+070.0162.40E+060.148↑[b](#tbl3fnb){ref-type="table-fn"}ns7GelsolinGSN8.40E+070.0162.50E+060.945↑[b](#tbl3fnb){ref-type="table-fn"}ns8Hyaluronan-binding protein 2HABP21.21E+070.0162.85E+060.461↑[b](#tbl3fnb){ref-type="table-fn"}ns**9HemopexinHPX0.74.85E+090.0161.05E+080.461↑**[b](#tbl3fnb){ref-type="table-fn"}**ns**10Insulin-like growth factor-binding protein complex acid labile subunitIGFALS7.09E+070.0163.95E+060.742↑[b](#tbl3fnb){ref-type="table-fn"}ns11Alpha-1-antichymotrypsinSERPINA33.65E+080.0311.23E+080.383↑[b](#tbl3fnb){ref-type="table-fn"}ns12KallistatinSERPINA44.54E+070.0167.25E+060.25↑[b](#tbl3fnb){ref-type="table-fn"}ns13Plasma serine protease inhibitorSERPINA54.60E+060.0165.58E+050.844↑[b](#tbl3fnb){ref-type="table-fn"}ns14Alpha-2-macroglobulinA2M−3.20E+090.016−4.84E+080.383↓[b](#tbl3fnb){ref-type="table-fn"}ns**Decrease in both**15Alpha-1 microglycoprotein (bikunin)AMBP−1.00E+090.016−3.25E+080.039↓[b](#tbl3fnb){ref-type="table-fn"}↓[b](#tbl3fnb){ref-type="table-fn"}16Apolipoprotein MAPOM−2.25E+070.016−1.50E+060.641↓[b](#tbl3fnb){ref-type="table-fn"}ns17AttractinATRN−3.18E+070.016−1.94E+070.109↓[b](#tbl3fnb){ref-type="table-fn"}ns18Cholinesterase (Butyrylcholine esterase)BCHE−1.94E+070.016−8.72E+060.063↓[b](#tbl3fnb){ref-type="table-fn"}ns19Complement C1r subcomponentC1R−1.11E+070.219−5.45E+060.008ns↓[b](#tbl3fnb){ref-type="table-fn"}20C4b-binding protein alpha chainC4BPA−1.80E+080.016−2.77E+070.383↓[b](#tbl3fnb){ref-type="table-fn"}ns21Monocyte differentiation antigen CD14CD14−2.90E+060.813−1.18E+070.039ns↓[b](#tbl3fnb){ref-type="table-fn"}22Complement Factor HCFH−3.90E+080.031−2.20E+070.641↓[b](#tbl3fnb){ref-type="table-fn"}ns23ClusterinCLU−5.50E+070.047−6.80E+070.195↓[b](#tbl3fnb){ref-type="table-fn"}ns**24Collagen alpha-3(VI)COL6A39.1−4.14E+040.031−3.63E+030.188↓**[b](#tbl3fnb){ref-type="table-fn"}**ns**25Carboxypeptidase N catalytic chainCBPN1−1.00E+070.016−6.39E+060.313↓[b](#tbl3fnb){ref-type="table-fn"}ns26Carboxypeptidase N subunit 2CPN2−6.16E+070.016−9.10E+070.016↓[b](#tbl3fnb){ref-type="table-fn"}↓[b](#tbl3fnb){ref-type="table-fn"}**27Fibulin-2 (EGF-containing fibulin-like extracellular matrix protein 1)EFEMP11.6−2.14E+070.016−8.66E+060.008↓**[b](#tbl3fnb){ref-type="table-fn"}**↓**[b](#tbl3fnb){ref-type="table-fn"}28Fibulin-1FBLN1−3.73E+070.016−2.41E+070.039↓[b](#tbl3fnb){ref-type="table-fn"}↓[b](#tbl3fnb){ref-type="table-fn"}29Fibrinogen alpha chainFGA−4.39E+060.047−4.69E+060.461↓[b](#tbl3fnb){ref-type="table-fn"}ns**30Insulin-like growth factor-binding protein 2IGFBP29−2.96E+070.016−1.71E+060.094↓**[b](#tbl3fnb){ref-type="table-fn"}**ns**31Inter-alpha-trypsin inhibitor heavy chain H2ITIH2−4.56E+080.047−3.70E+070.461↓[b](#tbl3fnb){ref-type="table-fn"}ns32Inter-alpha-trypsin inhibitor heavy chain H3ITIH3−4.17E+070.016−8.63E+060.078↓[b](#tbl3fnb){ref-type="table-fn"}ns**33Inter-alpha-trypsin inhibitor heavy chain H4ITIH41.4−4.80E+080.016−2.27E+080.055↓**[b](#tbl3fnb){ref-type="table-fn"}**ns**34Phosphatidylcholine-sterol acyltransferaseLCAT−1.52E+070.016−8.65E+060.148↓[b](#tbl3fnb){ref-type="table-fn"}ns35Galectin-3-binding proteinLGALS3BP−3.73E+070.047−3.84E+070.008↓[b](#tbl3fnb){ref-type="table-fn"}↓[b](#tbl3fnb){ref-type="table-fn"}36LumicanLUM−1.87E+080.016−9.11E+070.008↓[b](#tbl3fnb){ref-type="table-fn"}↓[b](#tbl3fnb){ref-type="table-fn"}**3772 kDa type IV collagenaseMMP22.3−1.30E+060.031−5.69E+050.063↓**[b](#tbl3fnb){ref-type="table-fn"}**ns**38Prostaglandin-H2 D-isomerasePTGDS−1.54E+070.031−7.10E+060.156↓[b](#tbl3fnb){ref-type="table-fn"}ns39Sulfhydryl oxidase 1QSOX1−4.66E+050.297−6.43E+050.039ns↓[b](#tbl3fnb){ref-type="table-fn"}40Heparin cofactor 2SERPIND1−3.60E+070.078−7.90E+070.039ns↓[b](#tbl3fnb){ref-type="table-fn"}41Plasma protease C1 inhibitorSERPING1−4.37E+080.016−5.66E+080.016↓[b](#tbl3fnb){ref-type="table-fn"}↓[b](#tbl3fnb){ref-type="table-fn"}**42Sex hormone-binding globulinSHBG1.8−3.82E+080.016−1.68E+070.008↓**[b](#tbl3fnb){ref-type="table-fn"}**↓**[b](#tbl3fnb){ref-type="table-fn"}43Alpha-2-HS-glycoproteinAHSG4.30E+080.297−1.06E+090.023ns↓[b](#tbl3fnb){ref-type="table-fn"}**Increase in SSNS Decrease in SRNS**44Complement Factor ICFI1.99E+070.016−1.75E+070.313↑[b](#tbl3fnb){ref-type="table-fn"}ns45TetranectinCLEC3B4.08E+070.016−2.39E+070.25↑[b](#tbl3fnb){ref-type="table-fn"}ns46Coagulation factor XIIF125.75E+070.016−2.40E+060.945↑[b](#tbl3fnb){ref-type="table-fn"}ns47ProthrombinF23.60E+080.047−2.65E+070.742↑[b](#tbl3fnb){ref-type="table-fn"}ns**48Fetuin BFETUB0.58.27E+060.109−3.32E+060.039ns↓**[b](#tbl3fnb){ref-type="table-fn"}**49Vitamin D-binding proteinVDB0.74.70E+080.031−4.10E+080.055↑**[b](#tbl3fnb){ref-type="table-fn"}**ns**50Insulin-like growth factor-binding protein 3IGFBP33.50E+060.047−4.75E+051↑[b](#tbl3fnb){ref-type="table-fn"}ns*51Corticosteroid binding globulinSERPINA61.05E+080.016−1.69E+070.461↑*[b](#tbl3fnb){ref-type="table-fn"}*ns*52Thyroxine-binding globulinSERPINA75.20E+060.734−1.05E+070.008ns↓[b](#tbl3fnb){ref-type="table-fn"}**53Antithrombin-IIISERPINC10.73.85E+080.016−4.75E+070.641↑**[b](#tbl3fnb){ref-type="table-fn"}**ns**54Pigment epithelium-derived factorSERPINF14.96E+070.031−9.90E+060.945↑[b](#tbl3fnb){ref-type="table-fn"}ns55Alpha-2-antiplasminSERPINF21.50E+080.031−1.09E+080.188↑[b](#tbl3fnb){ref-type="table-fn"}ns56VitronectinVTN1.85E+080.156−1.53E+080.016ns↓[b](#tbl3fnb){ref-type="table-fn"}**57AdiponectinADIPOQ1.8−8.86E+070.0161.99E+070.383↓**[b](#tbl3fnb){ref-type="table-fn"}**nsDecrease in SSNS Increase in SRNS**58Apolipoprotein A1APOA1−9.00E+080.3752.04E+090.047ns↑[b](#tbl3fnb){ref-type="table-fn"}59Apolipoprotein BAPOB−2.50E+070.0164.21E+060.844↓[b](#tbl3fnb){ref-type="table-fn"}ns60Apolipoproten C1APOC1−5.57E+080.0311.17E+080.133↓[b](#tbl3fnb){ref-type="table-fn"}ns61Apolipoprotein C2APOC2−3.62E+080.0166.50E+060.844↓[b](#tbl3fnb){ref-type="table-fn"}ns62Complement factor H-related protein 1CFHR1−9.10E+070.0162.35E+071↓[b](#tbl3fnb){ref-type="table-fn"}ns63ProperdinCFP−1.36E+070.0166.01E+060.195↓[b](#tbl3fnb){ref-type="table-fn"}ns64Hepatocyte growth factor activatorHGFAC−9.69E+060.0310.00E+000.25↓[b](#tbl3fnb){ref-type="table-fn"}ns65PerlecanHSPG2−1.49E+050.0310.00E+000.5↓[b](#tbl3fnb){ref-type="table-fn"}ns66VasorinVASN−2.77E+060.0314.55E+050.844↓[b](#tbl3fnb){ref-type="table-fn"}ns[^13][^14][^15][^16][^17][^18]Figure 2Candidate biomarkers able to predict steroid resistance and their informatics analysis to examine emergent properties. (a) Median intensity-based absolute quantification (iBAQ) areas (middle hash), interquartile range (IQR); boxed area and whisker for maximum and minimum values for candidate biomarkers able to predict steroid resistance were plotted for pre- and post-treatment samples for children with steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) (SSNS Pre, light circle; SSNS Post, dark circle; SRNS Pre, light triangle; SRNS Post, dark triangle). All the pretreatment samples were significantly different between the SSNS versus SRNS groups ([Table 2](#tbl2){ref-type="table"}). Post-treatment time point comparator is added for illustration purposes ([Table 3](#tbl3){ref-type="table"}). \**P* \< 0.05; \*\**P* \< 0.01. (b) Candidate proteins (*n* = 13) significantly differentiating pre-steroid exposure patient samples were analyzed by hierarchical clustering. Protein abundance (iBAQ scores) were normalized and scaled by the *clustergram* function in MatLab (MathWorks, Natick, MA). Values are expressed as a fractional value around the median. Gene names and fold-changes (SSNS to SRNS) for significantly regulated pretreatment plasma proteins were submitted for (c) canonical molecular pathways analysis and (d) network analysis by Ingenuity Pathways Analysis (IPA) to consider implications of abundance difference trends within the proteomic dataset. (c) The top 10 canonical molecular pathways illustrated show significant enrichment, including 2 highly enriched pathways (Farnesoid X receptor FXR/retinoid X receptor \[RXR\] activation and liver X receptor \[LXR\]/RXR activation). Ratio data demonstrate the fraction of the submitted gene names to the gene names contained within the canonical pathways. (d) The top canonical network included 2 downregulated (SSNS \< SRNS) and 6 upregulated (SSNS \> SRNS) proteins, of which 3 upregulated proteins (matrix metalloproteinase 2 \[MMP-2\], APOE, and adiponectin \[ADIPOQ\]) occupied network node space. Tumor necrosis factor (TNF) is a central node within this network and inference based on its known regulation of ADIPOQ, APOE, IFGBP2, and MMP-2 expression (Activation Z-score 0.152; overlap *P* \< 0.0001). ADIPOQ, adiponectin; HPX, hemopexin; SHBG, sex hormone--binding globulin; VDB, vitamin D binding protein. (c,d) Copyright © 2000--2017 Qiagen. The authors acknowledge that the networks and functional analyses were generated through the use of IPA (<https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/>).[@bib20]

Plasma Protein Abundance as a Function of Steroid Resistance {#sec2.4}
------------------------------------------------------------

A hierarchical clustering method with heatmap visualization was used to guide analysis of the predictor candidate biomarkers ([Figure 2](#fig2){ref-type="fig"}b). The visualization of individual patients on heatmap is shown in [Supplementary Figure S2](#appsec1) and analysis of the entire proteomic dataset is also included in [Supplementary Figures S3](#appsec1) and [S4](#appsec1) as supplemental results.

Pathway Mapping and Interaction Networking of Candidate Biomarkers {#sec2.5}
------------------------------------------------------------------

Ingenuity Pathway Analysis of predictive proteins (see [Table 2](#tbl2){ref-type="table"}) suggested 10 canonical pathways (*P* \< 0.01) and 1 significant protein-protein network ([Figure 2](#fig2){ref-type="fig"}c and d). The top 6 canonical pathways were as follows: (i) Farnesoid X receptor/retinoid X receptor activation, (ii) liver X receptor/retinoid X receptor activation, (iii) airway pathology in chronic obstructive pulmonary disease, (iv) acute-phase response signaling, (v) hepatic fibrosis/hepatic stellate cell activation, and (vi) extrinsic prothrombin activation pathway. The principal network for the predictive biomarkers was built using 8 of 13 submitted proteins, including ADIPOQ, APOE, EFEMP1, HPX, IGFBP2, MMP-2, antithrombin-III (SERPINC1), and SHBG. As shown in [Figure 2](#fig2){ref-type="fig"}d, 5 proteins (SHBG, EFEMP1, HPX, IGFBP2, and antithrombin-III \[SERPINC1\]) were positioned at network edges, whereas MMP-2, ADIPOQ, APOE, and VEGF-A were positioned as network nodes, with MMP-2 and APOE nodes under the indirect regulation (dashed lines) of the cytokine tumor necrosis factor.

The top 5 canonical pathways identified by Ingenuity Pathway Analysis of defining/mechanistic candidate marker gene names were (i) liver X receptor/retinoid X receptor activation, (ii) Farnesoid X receptor/retinoid X receptor activation, (iii) acute-phase response signaling, (iv) coagulation system, and (v) atherosclerosis signaling. The top 3 networks assembled by Ingenuity Pathway Analysis overlapped and had common disease/functional attributions that included metabolic disease, hematological system development and function, inflammatory response, cell death, and survival. Network 1, but not networks 2 and 3, contained candidate biomarkers as nodal components ([Supplementary Figure S5](#appsec1); MMP-2, IGFBP3, ADIPOQ, and F2).

Biomarker Validation {#sec2.6}
--------------------

Thirty-seven patients (*n* = 74 samples) comprising 24 SSNS and 13 SRNS patients were analyzed by immunoblotting with specific antibodies for the validation of several of the predictive and mechanistic candidate biomarkers discovered previously in the proteomics analyses ([Figure 3](#fig3){ref-type="fig"}). Albumin levels were analyzed as a reference protein and, as expected, it confirmed a significant difference between SSNS and SRNS post-treatment samples ([Figure 3](#fig3){ref-type="fig"}a and b). HPX was significantly increased in the SSNS post-treatment group, but not in the SRNS group ([Figure 3](#fig3){ref-type="fig"}a and b), thus corroborating the proteomic results ([Table 3](#tbl3){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}). APOL1 was increased in both the SSNS and SRNS groups post-treatment, while maintaining the differences in its levels both pre- and post-treatment between the 2 groups ([Figure 3](#fig3){ref-type="fig"}a and b). Although it corroborated some of the proteomics results (significant increase in SSNS and moderate increase in SRNS, [Table 3](#tbl3){ref-type="table"}), its confirmation also underscored its relevance as a predictive biomarker, as well as a biomarker of disease remission (difference between SSNS and SRNS both pre- and post-treatment, [Figure 3](#fig3){ref-type="fig"}). VDB was a very strong predictive marker of steroid resistance on validation, and it followed the same pattern between pre- and post-treatment as observed in the proteomics results ([Table 3](#tbl3){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}, and [Figure 3](#fig3){ref-type="fig"}a and b). SHBG, apolipoprotein A1 (APOA1), and ADIPOQ did not show differences in pretreatment between SSNS and SRNS, although both SHBG and ADIPOQ levels were altered differently in SSNS and SRNS. MMP-2 showed 2 bands, representing the active (lower band, 64 kDa) and proenzyme (upper band, 72 kDa) forms. The relative active form of MMP-2 was significantly increased in SSNS post-treatment, and thus appears to be a potential marker to differentiate steroid sensitivity from resistance ([Figure 3](#fig3){ref-type="fig"}a--c).Figure 3Biomarker validation studies of selected candidate biomarkers to predict or define steroid resistance in childhood nephrotic syndrome. (a) Validation graphs and (b) representative blots are shown from the analyses of 37 patients (*n* = 74 samples) comprising 24 steroid-sensitive nephrotic syndrome (SSNS) and 13 steroid-resistant nephrotic syndrome (SRNS) patients by immunoblotting with specified antibodies for the validation of selected predictive and defining biomarkers outlined in [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}. A control sample was run on every gel, and test patient samples were normalized to control by densitometry. (c) Western blot semiquantitative comparisons of the candidate biomarker matrix metalloproteinase 2 (MMP-2). MMP-2 immunoblotting of 54 patient samples (16 SSNS and 10 SRNS patients) showed 2 bands, representing the active (lower band, 64 kDa) and proenzyme (upper band, 72 kDa) forms of the enzyme. These were individually semiquantitated by densitometry and the active versus proenzyme ratios measured. Statistical significance was determined by unpaired or paired *t* tests using the GraphPad Prism software version 6.00 (LaJolla, CA) for Windows. *P* values were considered significant at *P* \< 0.05 (\**P* \< 0.05 vs. SSNS pretreatment; ^\#^*P* \< 0.05 vs. SSNS post-treatment; ^\$^*P* \< 0.05 vs. SRNS pretreatment). ADIPOQ, adiponectin; HPX, hemopexin; SHBG, sex hormone--binding globulin; VDB, vitamin D binding protein.

The immunoblot data for the variables sex (male/female), SHBG, VDB, HPX, APOAI, ApoL1, albumin, ADIPOQm and MMP2 were analyzed by logistic regression using a backward stepwise regression. The minimal features set remaining in the SSNS/SRNS classification model included ADIPOQ, VDB, and MMP2, but not sex. The ability of the immunoblot densitometry data for these 3 plasma proteins to classify patient samples was significant (*P* = 0.003), with a net improvement by --2log likelihood = 51.591 (Cox & Snell *R*^2^ value = 0.247; Nagelkerke *R*^2^ value = 0.332). Last, to evaluate the sensitivity and specificity for these proteins identified by logistic regression, a receiver operator characteristic curve was constructed ([Figure 4](#fig4){ref-type="fig"}) and the area under the curve was calculated to be 0.78.Figure 4Receiver operating characteristic (ROC) curve. Logistic regression analysis of confirmatory immunoblot studies identified vitamin D binding protein (VDB), adiponectin (ADIPOQ), and matrix metalloproteinase 2 (MMP-2) as a minimal, significant set of plasma proteins predicting steroid response. An ROC analysis for these 3 proteins to classify steroid response in patients with NS (*n* = 37 paired samples) returned an area under the curve of 0.78.

Proteomic Landscape With Different Approaches {#sec2.7}
---------------------------------------------

Additional analyses approaches outlined in [Supplementary Table S1](#appsec1) were applied to the proteins identified in the SSNS and SRNS pre- and post-treatment groups to develop candidate biomarker protein lists ([Supplementary Table S2](#appsec1)).

Conclusion {#sec3}
==========

NS is a kidney disease that affects both children and adults, and 20% to 50% of patients present with or subsequently develop clinical steroid resistance, which is associated with greatly increased risks for treatment side effects and disease progression. The current study tested the hypothesis that paired plasma proteomic sample analyses could identify candidate biomarkers able to either predict steroid resistance before initial treatment or mechanistically define critical molecular pathways/targets that regulate clinical steroid resistance. We used a pilot proteomic discovery approach in 30 paired plasma samples obtained before and after initial steroid treatment and identified a panel of 13 candidate protein biomarkers predictive of steroid resistance and several candidate biomarkers that mechanistically define specific molecular pathways/targets of clinical steroid resistance in NS. Candidate biomarkers found to predict steroid resistance included VDB, HPX, Fetuin-B (FETUB), and ADIPOQ ([Table 4](#tbl4){ref-type="table"}). Candidate protein biomarkers found to mechanistically define specific molecular pathways/targets associated with steroid resistance included VDB, HPX, SHBG, antithrombin-III (SERPINC1), Fetuin-B (FETUB), ADIPOQ, MMP-2, and APOA1. Subsequent confirmatory studies in 74 patient samples of several of these candidate biomarkers by immunoblotting confirmed a few auspicious biomarkers with high potential to be able to either predict steroid resistance or to mechanistically define molecular pathways that regulate steroid resistance in childhood NS ([Table 4](#tbl4){ref-type="table"}).Table 4Candidate protein biomarkers to predict or define molecular pathways/targets of steroid resistance in pediatric nephrotic syndromeProteinNamePredictive biomarker[a](#tbl4fna){ref-type="table-fn"}Defining biomarker[b](#tbl4fna){ref-type="table-fn"}ProteomicsIB[c](#tbl4fnc){ref-type="table-fn"}ProteomicsIB[c](#tbl4fnc){ref-type="table-fn"}COL6A3Collagen alpha-3(VI) chainXXIGFBP2Insulin-like growth factor-binding protein 2XXMMP272 kDa type IV collagenaseXXXAPOEApolipoprotein EXADIPOQAdiponectinXXXSHBGSex hormone--binding globulinXXXEFEMP1EGF-containing fibulin-like extracellular matrix protein 1XXITIH4Inter-alpha-trypsin inhibitor heavy chain H4XXHPXHemopexinXXXVDBVitamin D binding proteinXXXXSERPINC1Antithrombin-IIIXXAZGP1Zinc-alpha-2-glycoproteinXXFETUBFetuin-BXXAPOL1Apolipoprotein L1XXX[^19][^20]

Proteome profiling of urine, and in some cases serum or plasma, has been analyzed over the past decade in patients with NS using various approaches.[@bib17]^,^[@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26] More recently, proteomic profiling of patients with NS based on their histology and clinical phenotype has yielded a panel of proteins able to distinguish between these different groups.[@bib16]^,^[@bib17] These studies had important differences from the current study. First, both of these studies analyzed urine samples. Second, neither of these studies included analyses of pretreatment samples that could enable identification of truly predictive biomarkers before initiation of any therapy. Third, the NS classification of Choi *et al.*[@bib17] was based on histology (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy) and included only adult patients, whereas the classification of Bennett *et al.*[@bib16] was similarly based on SRNS versus SSNS in children. From the discovery set, a few proteins, such as VDB, antithrombin-III (SERPINC1), and HPX, were common between our predictive markers of SRNS versus SSNS, and the markers of Choi *et al*.,[@bib17] which were able to distinguish among minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy cases. However, none of these markers were validated in the study by Choi *et al.*[@bib17] In the Bennett *et al.*[@bib16] study (which had more commonalties in study design), of their 13 identified proteins, VDB, HPX, APOA1, TBG (thyroxine-binding globulin or SERPINA7), a closely related protein to Fetuin-B (Fetuin-A) and zinc-alpha 2 glycoprotein (AZGP1) were commonly identified in our discovery sets of either predictive or mechanistic biomarkers ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}). Of these, VDB, HPX, APOA1, Fetuin-B, and AZGP1 were also identified in our predictive set, of which VDB was validated in both studies. The current study extends these previous findings by combining the use of a state-of-the-art proteomics approach with analyses of paired plasma samples from highly phenotyped children presenting with NS in whom the pretreatment samples were fully verified to represent a "disease-only" state before the administration of even a single dose of steroids. Such careful phenotyping of samples is critical, as we have previously found that even a 30-minute exposure of podocytes to steroids can significantly alter their proteomic profile.[@bib27] Our use of paired samples obtained both pretreatment and post-treatment, when patients had been clinically declared to have either SSNS or SRNS, enabled us to search for potential biomarkers able to both predict subsequent clinical steroid resistance, as well as to search for molecular pathways and targets associated with steroid resistance versus steroid responsiveness.

HPX is a plasma protein with high affinity for heme. A variety of biological activities have been attributed to hemopexin, including both pro- and anti-inflammatory activities.[@bib28] Regarding NS, hemopexin has been shown to induce nephrin-dependent reorganization of the podocyte actin cytoskeleton,[@bib29] and to distinguish SRNS via a urine proteomics approach, although it was not identified as a candidate on validation by enzyme-linked immunosorbent assay (ELISA).[@bib16] Our studies showed that HPX could discriminate patients with SSNS versus SRNS pretreatment, and that steroid treatment significantly increased plasma HPX levels in SSNS (but not SRNS) patients.

APOA1 is an important component of HDL and it has been shown to be present in more heterogeneous forms in the plasma of patients with NS.[@bib30] Dyslipidemia is also a prominent feature of NS, and our study identified APOL1 and other apolipoproteins that could distinguish children with SSNS versus SRNS, both before and after steroid treatment.[@bib7]^,^[@bib8]^,^[@bib31], [@bib32], [@bib33], [@bib34], [@bib35]

Adiponectin (ADIPOQ) levels have also been shown to be increased in patients with NS.[@bib36] Our studies found that although adiponectin levels started lower and decreased with steroid treatment in children with SSNS, adiponectin levels started higher and increased further with steroid treatment in those with SRNS.

A few studies have implicated matrix metalloproteinases in the pathogenesis of NS.[@bib37]^,^[@bib38] We found a trend toward higher MMP-2 levels in children with SRNS versus SSNS, both before and following steroid treatment. MMP-2 comprises both an active and a proenzyme form, and our studies underscored a potential role for the relative ratios of these forms, rather than absolute levels, in distinguishing SSNS versus SRNS.[@bib39] Molecular weight forms consistent with higher active/proenzyme ratios in SSNS versus SRNS post-treatment, suggests that increases in this ratio may play a beneficial role in the clinical response to steroids.

Nephrotic rats exhibit urinary loss of SHBG-bound testosterone, and steroid-binding proteins such as SHBG act as gatekeepers of steroid hormone action in the plasma.[@bib40]^,^[@bib41] Our studies showed that SHBG levels increased with steroid treatment in SSNS but decreased in SRNS. These findings may simply reflect reduced urinary losses of SHBG in children with SSNS as they enter remission. However, given the reported role of SHBG in regulating steroid action, these findings may also identify a novel potential opportunity to enhance steroid responsiveness by supplementing or pharmacologically enhancing its production during steroid treatment.

VDB has recently emerged as a urinary marker of steroid resistance in NS, whereas vitamin D has also been reported to have a role in the protection of podocytes against NS-related injury.[@bib16]^,^[@bib42]^,^[@bib43] Our studies in addition identified a 3-protein predictive candidate biomarker panel (VDB, ADIPOQ, and MMP-2) with a significant ability to differentiate at disease presentation patients who will develop SRNS from those who will have SSNS (*P* = 0.003; area under the receiver operating characteristic curve = 0.78; [Table 4](#tbl4){ref-type="table"}).

This study had several limitations and strengths. Unlike some previous studies in which ELISA was used for confirmation of identified biomarkers, we used an immunoblotting confirmatory strategy. Although more labor intensive, this strategy enabled significantly improved specificity for the detection of proteins of interest. Many antibodies used in ELISAs and immunoblotting bind nonspecifically to other proteins, as we also observed in our blots. Immunoblotting enabled us to successfully circumvent this potential lack of specificity by performing quantitative densitometric analyses of bands, and identify only the proteins of interest. This was specifically relevant for VDB, which belongs to the same gene family and shares significant homology with albumin, and thus could confound confirmatory results using ELISA.[@bib44] This approach also allowed us to evaluate the active versus proenzyme fractions of MMP-2, which is a better marker of its activity than total MMP-2 levels.[@bib45] In addition, immunoblotting enabled the use of small sample volumes compared with ELISAs. To further enhance accuracy, we also used the same control sample in every gel and blot, enabling us to directly normalize all patient samples tested. A larger cohort will be needed in the future to validate the other biomarkers identified in the discovery analysis, as we were not able to validate them all in the present study. Our validation studies were targeted just toward the most relevant/significant markers known in NS or differentially expressed markers, and were also limited by commercial reagent availability (specific antibodies). The predictive and defining power of the identified proteins is likely to benefit from expanding the validation list in future studies.

Although most similar biomarker studies have been performed using urine, our studies used plasma samples. It would thus be of interest to attempt to further validate our identified biomarkers in urine samples from a larger and separate cohort in the future, and such studies are under way. However, identification of biomarkers in plasma is highly relevant, because it directly reflects the true concentrations of these proteins in blood, without perturbation by renal tubular secretion or reabsorption. Furthermore, SRNS typically presents clinically at older ages with higher average weight than children with SSNS. Because this is a typical generalized difference between the 2 groups, accounting for these confounders was not found to be essential and clinically relevant. Last, we are aware that some of the children with SRNS may have had an underlying genetic cause of disease. However, because these samples were collected over a decade, there were no provisions to screen them for monogenetic causes at that time. Despite this limitation, this study emphasizes differences between children with SRNS and SSNS that are clearly detectable at the time of clinical presentation, regardless of underlying genetic causes, and that would likely be more rapidly available and thus more clinically useful to treating physicians than genetic studies.

A major strength of this study was the evaluation of paired samples from each patient, both before any steroid treatment and following an average of approximately 7 weeks of daily oral steroids. This enabled us to use multiple approaches to analyze the dataset, including identification of potential biomarkers predictive of the subsequent clinical response to steroids, as well as to identify specific mechanistic molecular pathways and/or targets associated with both steroid response and steroid resistance. Because the discovery studies were limited to an all-female subgroup, we expanded our validation cohort to include male and more female patients and using an orthogonal (antibody-based) method, as has been done previously in similar studies.[@bib16] Logistic regression analysis for our candidate predictor biomarker classification of male and female patient samples did not identify sex as a significant classification variable. These logistic regression findings suggest additional studies on the mechanistic candidate biomarkers are justified. Notably, this same group of patient samples has also undergone plasma metabolomics analyses,[@bib46] and future studies will benefit from identification of additional relevant molecular pathways and biomarkers of SRNS using approaches that integrate the proteomics and metabolomics datasets.

In summary, the current studies used paired plasma samples from children with SSNS and SRNS obtained both before and after approximately 7 weeks of daily oral steroids to identify several candidate proteomic biomarkers with the potential to predict subsequent treatment response, and to define specific molecular pathways or targets associated with both steroid sensitivity and steroid resistance. In addition to NS, steroids are also a primary therapy for many other diseases, such as asthma, rheumatoid arthritis, autoimmune hepatitis, and ulcerative colitis. Interestingly, approximately 10% to 30% of these patients also present with or develop steroid resistance during their disease course, leading to increased risks for both drug toxicity and disease progression. Thus, further validation of these results could greatly improve our ability to predict the risk of clinical steroid resistance at disease onset for a large and diverse group of patients. These findings also could improve our understanding of the molecular mechanisms that regulate the clinical response to GCs and help identify potential future molecular targets to improve the treatment of NS as well as other conditions treated with steroids.
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**Supplementary Materials and Methods.**

**Figure S1.** Proteomics workflow for candidate biomarker selection.

**Figure S2.** Heat map with hierarchical clustering portraying individual patients.

**Figure S3**. Hierarchical clustering method with heatmap visualization of the entire proteomic data set.

**Figure S4**. Protein-protein interaction networks derived from unique 2-member HC heatmap cluster.

**Figure S5.** Ingenuity Pathway Analysis--identified molecular networks derived from defining candidate biomarkers.

**Table S1.** Various approaches used to identify additional proteins/molecular pathways that distinguish SSNS versus SRNS and pre- versus posttreatment samples.

**Table S2.** Proteins identified using various analyses (A--F from [Supplementary Table S1](#appsec1)) that distinguish SSNS versus SRNS and pre- versus posttreatment samples.
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[^4]: ns, not significant; SRNS, steroid-resistant nephrotic syndrome; SSNS, steroid-sensitive nephrotic syndrome.

[^5]: Significance determined by ^a^*t* test.

[^6]: binomial test.

[^7]: χ^2^ test.

[^8]: *P* \< 0.05.

[^9]: *P* \< 0.01.

[^10]: *P* \< 0.001.

[^11]: APP, acute-phase protein; EGFR, epidermal growth factor receptor; HDL, high density lipoprotein; IGF, insulin-like growth factor; SRNS, steroid-resistant nephrotic syndrome; SSNS, steroid-sensitive nephrotic syndrome.

[^12]: Entry not observed in "mechanistic analysis."

[^13]: EGF, epidermal growth factor; GC, glucocorticoid; iBAQ, intensity-based absolute quantification; ns, not significant; SRNS, steroid-resistant nephrotic syndrome; SSNS, steroid-sensitive nephrotic syndrome.

[^14]: Negative (−) values indicate a decrease in relative plasma abundance. Positive (+) values indicate an increase in relative plasma abundance.

[^15]: Bolded proteins are found in [Table 2](#tbl2){ref-type="table"}.

[^16]: Italicized proteins known to be responsive to GCs.

[^17]: Values represent difference in median values of post-treatment sample − pretreatment sample.

[^18]: *P* \< 0.05.

[^19]: Approaches defined in [Figure 1](#fig1){ref-type="fig"}.

[^20]: Immunoblotting.
